Analyst Rating Update on Sangamo BioSciences (SGMO)

Sangamo BioSciences (NASDAQ:SGMO) : 7 analysts are covering Sangamo BioSciences (NASDAQ:SGMO) and their average rating on the stock is 1, which is read as a Strong Buy. 7 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.

Sangamo BioSciences (NASDAQ:SGMO) : The consensus price target for Sangamo BioSciences (NASDAQ:SGMO) is $18.4 for the short term with a standard deviation of $6.58. The most optimist securities analyst among the 5 who monitor the stock believes that the stock can reach $30, however, the pessimist price target for the company is $14.

For this week, the average consensus of the company shares are rated as a Strong Buy.

Sangamo BioSciences (NASDAQ:SGMO): stock turned positive on Tuesday. Though the stock opened at $5.25, the bulls momentum made the stock top out at $5.58 level for the day. The stock recorded a low of $5.25 and closed the trading day at $5.56, in the green by 8.17%. The total traded volume for the day was 932,091. The stock had closed at $5.14 in the previous days trading.

In an insider trading activity, The director officer (President & CEO), of Sangamo Biosciences Inc, Lanphier Edward O Ii had unloaded 25,000 shares at $10.43 per share in a transaction on July 15, 2015. The total value of transaction was $260,750. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.